19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Jobs report Friday again. Here’s what to look for in the numbers [and let’s temper those expectati...
Read More >
Public construction in Pennsylvania and elsewhere continues to present substantial challenges to loc...
Read More >
Technology is rapidly evolving, and the use of Artificial Intelligence (AI), automation and robotics...
Read More >
On Wednesday, December 18, 2019, Obermayer Chair of the Government Contracting Department, Maria Pan...
Read More >
On December 20, President Trump signed into law the “Setting Every Community Up for Retirement Enha...
Read More >
In a market with soaring multiples, private equity buyers are increasingly on the hunt to mitigate h...
Read More >